Janux Therapeutics (JANX) Assets Average (2021 - 2026)
Janux Therapeutics (JANX) posted quarterly Assets Average of $1.0 billion for Q1 2026, down 3.91% year-over-year from $1.1 billion in Q1 2025, and little changed quarter-over-quarter from $1.0 billion in Q4 2025.
Janux Therapeutics (JANX) Assets Average (2021 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has reported Assets Average for 6 consecutive years, with $1.0 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average fell 3.91% year-over-year to $1.0 billion; the TTM figure through Mar 2026 stood at $1.0 billion (down 3.91% YoY), while the FY2025 annual figure was $1.0 billion, up 43.08% from the prior year.
- Assets Average held at $1.0 billion in Q1 2026 per JANX's latest filing, from $1.0 billion in the prior quarter.
- Across five years, Assets Average topped out at $1.1 billion in Q1 2025 and bottomed at $347.2 million in Q2 2023.
- Historically, Assets Average has averaged $641.5 million across 5 years, with a median of $534.7 million in 2024.
- Annual changes were most pronounced in 2023 — Assets Average dropped 7.89% — and 2024, when it soared 128.94%.
- Janux Therapeutics' Assets Average stood at $369.9 million in 2022, then increased by 3.72% to $383.6 million in 2023, then jumped by 128.94% to $878.3 million in 2024, then gained by 15.36% to $1.0 billion in 2025, then gained by 0.17% to $1.0 billion in 2026.
- Business Quant data shows JANX's Assets Average at $1.0 billion in Q1 2026, $1.0 billion in Q4 2025, and $1.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Janux Therapeutics | 984.58 Mn | 984.58 Mn | - | 1.02 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.02 Bn |
| Mar 31, 2026 | 1.01 Bn |
| Dec 31, 2025 | 1.01 Bn |
| Sep 30, 2025 | 1.03 Bn |
| Jun 30, 2025 | 1.04 Bn |
| Mar 31, 2025 | 1.06 Bn |
| Dec 31, 2024 | 878.27 Mn |
| Sep 30, 2024 | 693.22 Mn |
| Jun 30, 2024 | 690.20 Mn |
| Mar 31, 2024 | 534.70 Mn |
| Dec 31, 2023 | 383.63 Mn |
| Sep 30, 2023 | 364.18 Mn |
| Jun 30, 2023 | 347.23 Mn |
| Mar 31, 2023 | 358.48 Mn |
| Dec 31, 2022 | 369.88 Mn |
| Sep 30, 2022 | 380.56 Mn |
| Jun 30, 2022 | 376.98 Mn |
| Mar 31, 2022 | 374.21 Mn |
| Dec 31, 2021 | 385.45 Mn |
| Sep 30, 2021 | 393.95 Mn |